ArticleThorax2019
Article in Thorax, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- Approach to the Evaluation and Management of Interstitial Lung Abnormalities: An Official American Thoracic Society Clinical Statement.American journal of respiratory and critical care medicine · 2025Guideline
- Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.American journal of respiratory and critical care medicine · 2022Guideline
- Prevalence of Interstitial Lung Abnormalities (ILAs) in Italian Lung Cancer Screening Programs: A Monocentric Study.Journal of clinical medicine · 2026Article
- Behavioural changes in exposure patterns after genetic counselling among asymptomatic first-degree relatives of patients with pulmonary fibrosis and carriers of a telomere-related gene variant.ERJ open research · 2026Article
- Article
- Case report: Double-lung transplantation for Hermansky-Pudlak syndrome-associated pulmonary fibrosis and early-stage lung cancer.Frontiers in immunology · 2026Article
- Familial interstitial lung disease: emerging insights into screening and genetic risk.Frontiers in medicine · 2026Review
- Prognostic Impact of Quantitative CT Disease Extent and Pattern in Hypersensitivity Pneumonitis.medRxiv : the preprint server for health sciences · 2025Article
- The distribution and the clinical importance of MUC5B and TERT variants in Turkish patients with idiopathic pulmonary fibrosis.BMC pulmonary medicine · 2025Article
- Self-Reported Resilience During the COVID-19 Pandemic.JAMA network open · 2025Article
- Protein biomarkers of interstitial lung abnormalities in relatives of patients with pulmonary fibrosis.The European respiratory journal · 2025Article
- Screening relatives of familial pulmonary fibrosis patients: who, when, how and why?The European respiratory journal · 2025Article
- A Comprehensive Review of Interstitial Lung Abnormalities.Respirology (Carlton, Vic.) · 2025Review
- Current perspectives on interstitial lung abnormalities.The Korean journal of internal medicine · 2025Review
- Article
- An Overview of the Role of Genetic factors in Idiopathic Pulmonary Fibrosis: Insights from Epidemiology to Prognosis.International journal of medical sciences · 2025Review
- Progressive Early Interstitial Lung Abnormalities in Persons at Risk for Familial Pulmonary Fibrosis: A Prospective Cohort Study.American journal of respiratory and critical care medicine · 2024Article
- Genetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine.American journal of respiratory and critical care medicine · 2024Review
- Longitudinal assessment of interstitial lung abnormalities on CT in patients with COPD using artificial intelligence-based segmentation: a prospective observational study.BMC pulmonary medicine · 2024Observational
- Interstitial lung abnormality evaluated by an automated quantification system: prevalence and progression rate.Respiratory research · 2024Article
Corrections and comments
- Commented on by
Authors and funding
17 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundRelatives of patients with familial interstitial pneumonia (FIP) are at increased risk for pulmonary fibrosis. We assessed the prevalence and risk factors for preclinical pulmonary fibrosis (PrePF) in first-degree relatives of patients with FIP and determined the utility of deep learning in detecting PrePF on CT.
methodsFirst-degree relatives of patients with FIP over 40 years of age who believed themselves to be unaffected by pulmonary fibrosis underwent CT scans of the chest. Images were visually reviewed, and a deep learning algorithm was used to quantify lung fibrosis. Genotyping for common idiopathic pulmonary fibrosis risk variants in
findingsIn 494 relatives of patients with FIP from 263 families of patients with FIP, the prevalence of PrePF on visual CT evaluation was 15.6% (95% CI 12.6 to 19.0). Compared with visual CT evaluation, deep learning quantitative CT analysis had 84% sensitivity (95% CI 0.72 to 0.89) and 86% sensitivity (95% CI 0.83 to 0.89) for discriminating subjects with visual PrePF diagnosis. Subjects with PrePF were older (65.9, SD 10.1 years) than subjects without fibrosis (55.8 SD 8.7 years), more likely to be male (49% vs 37%), more likely to have smoked (44% vs 27%) and more likely to have the
interpretationPrePF is common in relatives of patients with FIP. Its prevalence increases with age and the presence of a common
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.